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(Standard uptake value level). Equally in-
tense uptake in N2 groups is likely to have
a poorer prognosis than low-level single
station uptake. A suspicious contralateral
pulmonary nodule seen on CT is likely to
be more significant if it shows increased
uptake on CT/PET imaging.
If there is sufficient evidence, we
would ask the authors to see if these
unrepresented but well-recognized areas
could be incorporated into the revised
staging scheme. Future staging revisions
may need to incorporate the developing
prognostic information available from
anatomic and particularly metabolic im-
aging techniques.
J. Vimal Raj, MBBS, FRCR
Richard Coulden, FRCR, FRCP
James Entwisle, MBBS, MRCP, FRCR
University Hospitals of Leicester
Glenfield Hospital
Leicester, United Kingdom
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Reply to “Cancer
Staging
Correspondence 2”
In Reply:
We thank Drs Raj, Coulden, and
Entwistle for their interest in the Interna-
tional Association for the Study of Lung
Cancer (IASLC) Staging Project, their
kind comments and insightful questions.
Our recommendations for the 7th
Edition of tumor, node, metastasis
(TNM)1 were based upon the largest
database ever accumulated for the study
of Lung Cancer.2 It was a global effort
with colleagues from 46 data sources in
over 19 countries contributing data on
cases treated by all modalities of care,
enrolled over a relatively short period
from 1990 to 2000. However, when col-
lecting data retrospectively to build a
large database as quickly as possible one
has to take what data is available. Much
of the data with which we were provided
had been collected for other purposes,
such as clinical trials, and the staging
data collected was often limited to those
fields shown to be important in earlier
editions of TNM. Consequently, there
were many issues that we would have
wished to evaluate on which we had no
data. Many of these areas will be in-
cluded in the prospective database in-
tended as the next phase in this project.
The amount of detail that we can collect
will be dependent upon the level of
funding we obtain and upon identifying
appropriate collaborators who are able
to supply the minimum dataset.
We agree that the issue of lym-
phangitis identified by Raj and colleagues
is inadequately covered by the “optional
descriptors” for lymphatic invasion pres-
ently offered in the 6th Edition of either
the International Union Against Cancer
(UICC) TNM Classification of Malignant
Tumors3 or the American Joint Commit-
tee on Cancer (AJCC) Manual of Cancer
Staging.4 We hope to study this in more
detail in the prospective data base.
Our N-descriptors subcommittee
has reported the results of exploratory
analyses covering the prognostic role of
involvement of individual lymph nodes
and various combinations of nodal sta-
tions.5 In addition, this group has devel-
oped an “IASLC” nodal chart, about to
be submitted to the Journal of Thoracic
Oncology, which for the first time will
reconcile the differences between the
“Naruke” nodal chart6 and that of
“Mountain and Dressler.”7 These devel-
opments should allow our prospective
data base better to unravel the prognos-
tic interaction between the position and
bulk of involved lymph nodes. We in-
tend also to collect data on the size of
the most relevant nodal deposit in our
prospective data base.
Sadly in clinical staging the deci-
sion as to how much of a bulky tumor
mass represents primary tumor and how
much is due to nodal disease will remain a
judgment call. General rule 4, however,
suggests that “if there is doubt concerning
the correct T, N, or M category to which a
particular case should be allotted, then the
lower (i.e., less advanced) category should
be chosen. This will also be reflected in
the stage grouping.”
Positron emission tomography
scanning was not widely available dur-
ing the period of our data collection. The
European Lung Cancer Working Party,
on our behalf, undertook a meta-analysis
of the prognostic significance of the
maximum standardized uptake value in
the primary tumor at presentation, re-
cently published in the Journal of Tho-
racic Oncology.8 Our prospective data-
base will allow much more thorough
assessment of the prognostic informa-
tion available with positron emission to-
mography scanning.
Finally, we would like to take this
opportunity to inform our colleagues in
the lung cancer community of the TNM
Helpdesk available by following the links
at www.uicc.org. This resource allows
one to direct questions to experts in the
field of staging and lung cancer, and is
monitored by the UICC for proposals for
future revisions.
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Third-Generation
Chemotherapy Agents
in the Treatment of
Advanced Non-small
Cell Lung Cancer: A
Meta-Analysis
To the Editor:
The Journal of Thoracic Oncology
has published in its September 2007 issue
a meta-analysis about third-generation
agents in the treatment of advanced non-
small cell lung cancer.1 The authors have
considered the randomized trials pub-
lished until March 2004. Nineteen studies
were selected for the analysis. Some trials
published before 20042–8 were not in-
cluded without very obvious reasons. All
are European authors or publications in
European journals. Vinblastine has to be
considered as one of the active second-
generation drugs, the place of epirubicin
among those is more debatable. In addi-
tion, some important studies have been
published after 2004. It is not clear why
the authors have limited the literature re-
view to March 2004 to perform the meta-
analysis and to publish 3 years later with-
out updating the results.
In addition, a subgroup meta-analy-
sis of the trials comparing third-generation
doublets with second-generation triplets
would probably show no survival differ-
ence as suggested on Figure 5. Two
recently published studies9,10 might be
added to increase the power of the ag-
gregation, although carboplatin has been
used instead of cisplatin. This is an im-
portant question because those types of
triplets are still used in daily practice for
multiple reasons including cost.
Finally, overall survival rather
than 1-year survival should have been
considered, an end point fully possible
in literature-based meta-analyses.
Jean-Paul Sculier, MD, PhD
Anne-Pascale Meert, MD, PhD
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Third-Generation
Chemotherapy Agents
in the Treatment of
Advanced Non-small
Cell Lung Cancer: A
Meta-Analysis
To the Editor:
We would like to thank Drs. Scu-
lier and Meert for their constructive
criticism of our recent meta-analysis
of third-generation agents in the treat-
ment of advanced non-small cell lung
cancer (NSCLC).1 Their comments re-
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